StockNews.AI
CGEN
StockNews.AI
22 days

Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025

1. Compugen to present analysis on COM701 at ESMO 2025 in Berlin. 2. COM701 is targeting platinum-resistant ovarian cancer in heavily pretreated patients. 3. Presentation scheduled for October 18, details available on Compugen's website. 4. COMP701 could be a first-in-class therapeutic option in immunotherapy space. 5. Compugen's pipeline includes multiple promising candidates with strong market potential.

5m saved
Insight
Article

FAQ

Why Bullish?

The presentation of COM701 suggests strong R&D progress, potentially attracting investors. Historical examples show that positive trial data often correlates with stock price increases in biotech.

How important is it?

The article highlights critical upcoming events for COM701, with potential market impact. The relevance of trial outcomes to CGEN's future and investor interest enhances its significance.

Why Long Term?

Successful presentation outcome could lead to future partnerships or funding, enhancing valuation. Similar firms often see sustained investor interest post successful trials.

Related Companies

AZNGILD
, /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a pooled analysis of data from three Phase 1 trials evaluating COM701 as monotherapy and combination therapy in heavily pretreated platinum resistant ovarian cancer patients at ESMO 2025, being held on October 17-21, 2025, in Berlin, Germany. Poster details: Title: COM701 in Ovarian Cancer: A Pooled Analysis of 3 Phase 1 Clinical Trials Speaker: Dr. Oladapo Yeku, Massachusetts General Hospital, Boston, MA, U.S.Poster presentation number: 1196PDate of poster presentation: Saturday, October 18; 12:00-12:45 CEST The poster will be available in the publications section of Compugen's website, www.cgen.com About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address various mechanisms to activate the immune system against cancer. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Company contact:Yvonne Naughton, Ph.D.Vice President, Head of Investor Relations and Corporate CommunicationsEmail: [email protected] Tel: +1 (628) 241-0071 SOURCE Compugen Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News